Evidence map›Paper›PMID 36948419›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Bioorthogonal nanozymes for breast cancer imaging and therapy.

Xianzhi Zhang, Yuanchang Liu, Jeerapat Doungchawee, Laura J Castellanos-García, Kristen N Sikora, Taewon Jeon, Ritabrita Goswami, Stefano Fedeli, Aarohi Gupta, Rui Huang and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Can nanozymes achieve more than enzymes?Nature reviews. Materials · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Xianzhi ZhangDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Yuanchang LiuDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Jeerapat DoungchaweeDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Laura J Castellanos-GarcíaDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Kristen N SikoraDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Taewon JeonDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA; Molecular and Cellular Biology Graduate Program, University of Massachusetts Amherst, 230 Stockbridge Road, Amherst, MA 01003, USA.
Ritabrita GoswamiDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Stefano FedeliDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Aarohi GuptaDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Rui HuangDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Cristina-Maria HirschbiegelDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Roberto Cao-MilánDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Prabin K D MajhiDepartment of Veterinary and Animal Science, University of Massachusetts Amherst, 661 N Pleasant Street, Amherst, MA 01003, USA.
Yagiz Anil CicekDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Liang LiuDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
D Joseph JerryDepartment of Veterinary and Animal Science, University of Massachusetts Amherst, 661 N Pleasant Street, Amherst, MA 01003, USA.
Richard W VachetDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA.
Vincent M RotelloDepartment of Chemistry, University of Massachusetts, 710 North Pleasant Street, Amherst, MA 01003, USA. Electronic address: rotello@chem.umass.edu.
University of Massachusetts Amherst · US

Funding

Metabolomics Administrative Supplement: Disruption of parity-induced tumor suppressor pathways by xenoestrogen exposures during pregnancyU01ES026140 · NIEHS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI JERRY, D. JOSEPH, SCHNEIDER, SALLIE SMITH · 2015 to 2019
$3.7M
Chemistry-Biology Interface Predoctoral Training GrantT32GM139789 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ERIC Robert STRIETER · 2021 to 2026
$3.4M
Targeting of Bio-orthogonal Chemotherapeutic Nanozymes to Tumor-Associated MacrophagesR01EB022641 · NIBIB · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ROTELLO, VINCENT M. · 2017 to 2024
$3.0M
NIBIB NIH HHS R01 EB022641NIEHS NIH HHS U01 ES026140NIGMS NIH HHS T32 GM139789
6 · The paper itself

Abstract

Bioorthogonal catalysis via transition metal catalysts (TMCs) enables the generation of therapeutics locally through chemical reactions not accessible by biological systems. This localization can enhance the efficacy of anticancer treatment while minimizing off-target effects. The encapsulation of TMCs into nanomaterials generates "nanozymes" to activate imaging and therapeutic agents. Here, we report the use of cationic bioorthogonal nanozymes to create localized "drug factories" for cancer therapy in vivo. These nanozymes remained present at the tumor site at least seven days after a single injection due to the interactions between cationic surface ligands and negatively charged cell membranes and tissue components. The prodrug was then administered systemically, and the nanozymes continuously converted the non-toxic molecules into active drugs locally. This strategy substantially reduced the tumor growth in an aggressive breast cancer model, with significantly reduced liver damage compared to traditional chemotherapy.

Indexed as

Breast NeoplasmsNanostructuresCatalysisCell MembraneDiagnostic ImagingFemaleHumansAnticancer therapyBioorthogonal catalysisBioorthogonal nanozymesLA-ICP-MS imagingNanocatalystsProdrug activationPro-fluorophore activation

Identifiers

PMID36948419
PMCPMC10164715
OpenAlexW4360599859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.